🇺🇸United States·March 19, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 19, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (34 new), dominant themes include aggressive liquidity raises via high-interest debt ($225M American Vanguard term loan, $3.75M SmartKem notes), equity offerings (SAB Biotherapeutics public offer, Twin Vee $1.7M ATM), and covenant amendments/extensions signaling covenant breaches (Cannabist forbearance to Mar25 2026, VINCE Holding receivables tweaks). Nasdaq/NYSE delisting notices hit AVAX ONE, Skye Bioscience, Getty Images for sub-$1 bids over 30 days, amplifying small-cap distress. No broad YoY revenue declines disclosed, but debt reductions (DevvStream -$5.9M net) and refinancings (Wolfspeed $475.9M lower-cost notes) provide relief outliers; forward-looking catalysts cluster in Q2/Q3 2026 closings (Mount Logan acquisition, Collegium AZSTARYS deal). Portfolio trends: 12+ equity offerings risking dilution (avg ~$50M targeted), 8+ credit amendments (e.g., AES change-of-control for merger), 1 RSA (DISH DBS potential Ch11); mixed sentiment (20 positive, 15 neutral, 10 negative). Implications: elevated bankruptcy risk in biotechs/microcaps, watch Mar25 Cannabist deadline and Nasdaq hearings for forced reverse splits/buyouts.

50 high priority50 total filings

🇺🇸United States·March 18, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 18, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive liquidity pursuits through debt facilities, equity issuances, note extensions, and credit amendments, with 18 companies (58%) announcing new/expanded financing amid potential distress signals like Nasdaq delisting notices in 2 cases and dilutive convertible notes in 5. Period-over-period data is sparse but highlights outliers: Ovid Therapeutics revenue surged 1117% YoY to $7.3M with opex down 20% to $49.7M and net loss halved to $17.4M, contrasting minimal quantitative trends elsewhere. Positive catalysts include M&A (e.g., Independent Bank's $70.2M accretive deal, ConnectM's defense acquisition) and buybacks (ExlService's $125M ASR), while risks cluster around equity dilution, reverse splits, and compliance deadlines into Q3-Q4 2026. Portfolio-level patterns show capital allocation skewed to debt preservation (e.g., Hilton, Socket Mobile extensions) over returns, with no insider buying/selling clusters but related-party deals in 4 filings signaling governance watchpoints. Forward-looking data builds a catalyst calendar heavy on approvals, closings, and trial readouts, implying short-term volatility in microcaps. Overall, distress signals are mixed with turnaround financing opportunities, but Nasdaq risks and high-interest notes flag 7 high-risk names warranting avoidance.

31 high priority31 total filings

🇺🇸United States·March 17, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 17, 2026

Across 42 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity maneuvers via high-cost convertible notes, equity offerings, and debt restructurings (e.g., 10+ issuances of notes/preferred with 15-22% effective rates), Nasdaq compliance failures (4 cases with delisting/reverse split risks), and covenant amendments signaling near-term stress, amid limited explicit YoY/QoQ data but clear patterns of debt settlements reducing burdens (e.g., Integrated Rail settled $705k, i-80 Gold retired $165M). Positive offsets feature major contracts (Duos $176M over 36 months), grants (Clene $8M), and M&A (Public Storage acquiring NSA), with sentiments skewing positive/neutral in 70% of cases despite distress focus. Critical developments like Urgent.ly's imminent delisting and New Fortress Energy's RSA (diluting shareholders to 35%) heighten bankruptcy risks, while refinancings (Indivior $500M at 0.625%, Beazer +43.8% facility) provide relief. Portfolio-level: Small-cap biotechs/tech show repeated dilution/equity raises (12 cases), airlines/construction deferrals indicate capex cuts, no broad margin compression trends evident but liquidity covenants relaxed in 3 filings. Implications: Heightened short opportunities in non-compliant names, long setups in turnaround financings with catalysts.

42 high priority42 total filings

🇺🇸United States·March 16, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 16, 2026

Across 38 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is proactive debt refinancing and extension, with 18 companies (e.g., Airbnb $2.5B notes to repay 0% convertibles, Waste Connections $600M notes, Duke Energy credit extension to 2031) issuing longer-term debt at higher rates (4.4%-6.75%) to manage short-term maturities, signaling avoidance of immediate liquidity crunches amid elevated interest expenses. Real estate players like Armada Hoffler ($562M asset sale for deleveraging to 5.5x-6.5x net debt/EBITDA) and Ares Commercial (facility extension to Dec 2026) show portfolio simplification, while biotech/health firms (Alto $120M placement, Zevra debt-free post-sale) raised capital for pipelines. Period-over-period trends reveal mixed results: Urgent.ly Q4 revenue +4% YoY/gross margin +400bps to 26% but FY revenue -10% YoY/cash down to $5.3M; TeraWulf FY2025 net loss $661M on $168.5M revenue; Spirit Airlines Chapter 11 projects FY26 revenue +6.1% YoY to $3B but net loss $111M. Distress signals include Lyra Therapeutics delisting (March 17, 2026), Outlook Therapeutics going concern (cash $8.7M insufficient), Greenland Nasdaq deficiency. Forward-looking catalysts cluster mid-2026 (e.g., AHRT closings, WisdomTree acquisition Q2), with no broad insider selling but capital allocation favoring deleveraging over dividends/buybacks. Portfolio-level: Margin expansions in 3/5 reporting firms (avg +200bps QoQ) offset by revenue declines in 4/10 (avg -8% YoY), highlighting sector-specific resilience in refinancing markets.

38 high priority38 total filings

🇺🇸United States·March 13, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 13, 2026

Across 41 8-K filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive financing maneuvers (e.g., credit amendments, ATM offerings, debt issuances totaling billions) to bolster liquidity amid scattered distress signals like Nasdaq/NYSE listing deficiencies in 4 companies and debt-for-equity swaps indicating balance sheet strains. No broad period-over-period declines are quantified, but inferred trends show 6/41 companies executing dilutive equity raises or exchanges (e.g., NextNRG's $1.75M debt-for-3.18M shares), contrasting with positive capital raises like Venture Global's $8.6B CP2 Phase 2 FID. Critical developments feature imminent delistings (Bio Green Med's preferred stock suspension March 23, 2026) and compliance grace periods (Talphera until Sept 7, 2026; Azitra until Apr 1, 2027), signaling heightened bankruptcy risks for microcaps in pharma/biotech. Portfolio-level patterns reveal sector-agnostic distress financing, with energy/oil (Battalion, 1606 Corp) pursuing accretive acquisitions while tech/pharma (Azitra, Talphera) face equity erosion. Overall, 22/41 neutral/positive sentiments mask underlying pressures, urging vigilance on dilution and listing catalysts for short-term trading opportunities.

41 high priority41 total filings

🇺🇸United States·March 12, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 12, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes reveal acute liquidity pressures driving 28+ capital raises/debt refinancings (e.g., $30M Longeveron private placement, $673M Dianthus equity), 12 credit amendments/waivers signaling covenant strain (XBP eliminating min availability, NGL ABL cut to $425M), and 5 delisting/reverse split risks (Cryo-Cell NYSE warning, Allurion to OTC, CXApp extension to Sep 2026). Period-over-period data sparse but highlights distress: Universal Electronics FY2025 sales -7% YoY to $368M, Q4 -21% to $87M despite margin expansion to 29.7% and op cash $23.6M; no broad YoY revenue growth, with declines/outliers in sales volumes/cash burn implied across microcaps. Insider activity minimal, but board changes (Turtle Beach activist settlement, Beneficient Hicks appt) suggest governance shifts amid distress. Forward-looking catalysts cluster in Q2-Q4 2026: trial readouts (Longeveron 3Q26), mergers (NIMU Jun30), note redemptions (Chemours 2027 notes). Portfolio implications: broad small/midcap distress via dilutive equity (NIMU 95.5% dilution, ECD 207M shares), higher-cost debt (Chemours 7.875% vs prior 5.75%), but successful raises extend runways (Firefly to 2027 lockups); short high-dilution names, buy post-stabilization refinancings.

50 high priority50 total filings

🇺🇸United States·March 11, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 11, 2026

Across 32 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq minimum bid price non-compliance (GameSquare, VYNE Therapeutics, SmartKem) granting extensions to Sep 2026, signaling persistent stock price weakness and delisting risks; dilutive financings via convertible notes/promissory notes (CERO Therapeutics $937.5k note at $0.05 conversion, SunPower $10M debenture at $2.50/share, Liberty Star $110k note); defensive shareholder rights plans (Starz at 17.5% trigger, Enzon extension); and liquidity support through credit facilities/extensions (Consolidated Edison $3.5B revolver, Advantage Solutions ABL amendment). Positive M&A offsets distress with Cintas/UniFirst $5.5B deal at 8.0x EBITDA (Cintas Q3 rev +8.9% YoY to $2.84B), Sphere 3D/Cathedra bitcoin mining merger (53MW capacity), Aureus/Powerus drone merger ($50M investment). Limited period trends show revenue growth outliers (Cintas +8.9% YoY organic +8.2%), but no widespread margin compression or YoY declines; neutral/mixed sentiment dominates (22/32), with 6 positive. Implications: Heightened short-term volatility from compliance deadlines, dilution risks eroding equity value, but M&A catalysts offer turnaround potential in services/tech.

32 high priority32 total filings

🇺🇸United States·March 10, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 10, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream, key themes include widespread dilutive equity raises (12+ companies, e.g., AN2 $40M at $2.85/share ~20% dilution potential, US Energy $8.2M), debt refinancings/extensions (15+ firms like AECOM $2.95B facilities, Hallador $120M to 2029), and Nasdaq delisting risks/reverse splits (5 cases: SolarMax, OSR Holdings, ClearSign 1:10, Origin 1:30, PMGC 6:1) signaling microcap distress. One outright bankruptcy confirmation (Nine Energy prepackaged plan in 33 days). Period-over-period trends mixed: EBITDA -4% YoY at Walker & Dunlop to $316M amid volume drops; KDP Coffee sales +1% YoY to $4.7B but net income -5% YoY to $700M, OCF +37% YoY to $629M; BlackLine margins +6% over 2 years with 2026 revenue guide 9.1-9.6%. Larger caps show capital access strength (Eaton $8.5B notes, FIS $6.8B), while biotechs/energy services cluster distress signals. Portfolio implications: Distress confined to small caps (low participation warrant exchanges like Guided 22.7%), potential alpha in post-reorg plays but contagion risk from Nasdaq failures.

45 high priority45 total filings

🇺🇸United States·March 10, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 10, 2026

The USA Bankruptcy & Insolvency stream features one key filing from Nine Energy Service, Inc., confirming its Amended Joint Prepackaged Chapter 11 Plan of Reorganization on March 4, 2026, just 33 days after petitioning on February 1, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas (Case No. 26-90295). This rapid prepackaged process, backed by an RSA with over 70% of Senior Secured Notes holders and 100% of Prepetition ABL Claims holders, and completed with no unresolved objections, underscores acute debt distress in the energy services sector but demonstrates strong creditor alignment for a swift emergence. No period-over-period financial metrics, forward-looking guidance, insider trading activity, capital allocation details, or operational metrics were disclosed, limiting quantitative trend analysis but amplifying the negative sentiment (rated negative, materiality 10/10). Market implications include likely dilution or cancellation of existing equity, potential trading halts or delistings, and a cleaner balance sheet post-reorg as a portfolio-level signal of ongoing insolvency pressures in cyclical energy subsectors. This isolated event highlights broader themes of creditor-driven restructurings amid commodity volatility, with no cross-filing comparisons available due to n=1.

1 high priority1 total filings

🇺🇸United States·March 09, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 09, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive capital raising via PIPEs ($85M Korro, $30M MGNC commitment), ATMs ($100M enGene), private placements ($15M Battalion, $11M Envirotech), and debt refinancings/securitizations ($1.6B Optimum, $900M Genesis revolver), signaling liquidity crunches or preemptive balance sheet fortification amid potential distress. Sparse period-over-period data reveals cost discipline in biotech (Spruce opex -40% YoY to $36.5M, net loss improved 26% to $39M) and operational upticks (Battalion oil prod +1,200 bpd Jan vs Dec), but tightening credit covenants (ProFrac availability cut to $275M, min liquidity $45M) and Nasdaq warnings (Cypherpunk < $1 bid 30 days) underscore distress risks. Direct bankruptcy activity limited to TPI Composites' Ch11 asset sale ($20M), with forbearance extensions (Cannabist to Mar 17) and collateral pledges (Jaguar $10.8M note) as red flags. M&A/asset sales (Lisata acquisition $5/share + CVR, Alexanders $235M property) provide cash influxes, while buybacks (United Therapeutics $2B, SLM $200M ASR) reflect conviction in non-distressed names. Portfolio-level: 18/50 filings involve equity dilution, 12 credit amendments/refis (mostly neutral-positive), implying sector-wide deleveraging but vulnerability to covenant breaches; opportunities in post-sale rebounds, risks in biotech trial failures.

50 high priority50 total filings

🇺🇸United States·March 06, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 06, 2026

The 51 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in listing compliance failures, with at least 10 companies (Traeger, Presurance Holdings, Offerpad, Jaguar Health, Beyond Meat, Iveda, Nerdy, Borealis Foods, United States Antimony, Spirit Aviation) cited for sub-$1.00 bid prices over 30 days, triggering 180-day cure periods often reliant on reverse stock splits approved in late 2025/early 2026. Debt restructurings and waivers dominate distressed signals (Nortech covenant waivers on Leverage Ratio/EBITDA, Gran Tierra 90% note exchange at higher 9.75% coupon), alongside impairments (Western Alliance $126.4M non-cash charge) and bankruptcy contexts (Spirit ongoing Ch.11 since Aug 2025). Positive counter-trends include sizable financings (Dave $175M conv notes with $70.5M buybacks, Core Scientific $500M loan expandable to $1B, Solid Biosciences $240M placement extending runway to H1 2028) and M&A (Day One $2.5B acquisition at 68% premium). No aggregate YoY/QoQ revenue/margin trends available across filings, but liquidity injections via $20M+ raises (Allarity, Honeywell up to $16B notes) signal aggressive survival tactics amid neutral-to-mixed sentiments (avg materiality 8/10). Portfolio implications: elevated short-term delisting/bankruptcy risks in small-caps, but select turnarounds via premium deals and debt extensions offer alpha for contrarians.

51 high priority51 total filings

🇺🇸United States·March 05, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 05, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream covering 51 filings from March 5, 2026, distress signals are limited with only two active Chapter 11 cases (Cumulus Media prepackaged plan with 72% support, TPI Composites asset sales amid DIP default), overshadowed by 20+ positive financings/refinancings (e.g., Pulmonx $60M term loan, Sunrise Realty $165M rev fac expansion) and debt tenders (Sirius XM $499M repurchased, Matador $420M). Period-over-period trends show mixed revenue performance: growth in OptimizeRx (+19% FY2025 YoY), Full House (+3.4% Q4 2025 YoY), but declines in GoPro (-19% FY2025 YoY) and implied sector weakness (Cumulus declining broadcast). Reverse stock splits in 5 small caps (Reviva 1:20, Aditxt/Sky Quarry 1:8, Salarius 1:12) flag microcap distress, while capital allocation leans bullish with buybacks (EPAM $300M ASR, OptimizeRx $10M program) and divestitures (Six Flags $331M for debt paydown, Community Health $112M). Forward-looking catalysts cluster in Q2 2026 (deal closings, approvals), suggesting deleveraging and liquidity boosts could stabilize portfolios. Portfolio implication: overweight structured distress resolutions and financing winners, underweight reverse-split microcaps amid Nasdaq deficiencies (Fly-E).

51 high priority51 total filings

🇺🇸United States·March 05, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 05, 2026

Cumulus Media Inc., the sole filing in this Bankruptcy & Insolvency intelligence stream, announced a prepackaged Chapter 11 plan of reorganization, highlighting severe liquidity pressures and a declining broadcast radio industry with no quantified operational improvements. Key creditors holding 72.05% of 2029 Secured Debt Claims have committed support via a Restructuring Support Agreement, signaling likely plan confirmation but underscoring deep financial distress. The debtors' board strongly recommends acceptance by the April 7, 2026 voting deadline, yet equity holders face probable wipeout or severe dilution in this negative sentiment (10/10 materiality) scenario. No period-over-period financial trends, insider trading, or capital allocation details were quantified, but ongoing industry decline points to structural headwinds. Market implications include heightened volatility for CUMULUS MEDIA INC (CMLS) equity, potential short opportunities, and distressed debt plays ahead of case commencement.

1 high priority1 total filings

🇺🇸United States·March 04, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 04, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive debt management and refinancing (seen in 20+ filings like Alliant Energy's $400M credit, Cooper-Standard's $1.1B notes at lower 9.25% vs prior 13.5%), signaling stabilization efforts amid isolated acute distress (1 bankruptcy, 1 delisting). Period-over-period trends where available show mixed revenue (Babcock & Wilcox flat Q4 YoY at $161M, Smith Micro -20% Q4/-16% FY2025 YoY, Aquestive +10% Q4 but -3% FY), but improving profitability (Babcock Adj EBITDA +53% Q4/+107% FY, Smith Micro net losses narrowed FY $30.1M from $48.7M). Capital allocation leans toward deleveraging (Sabre redeemed $91.6M notes, Franklin Street refinanced $320M at 9%), with M&A/divestitures (SSR Mining $1.5B mine sale, Farmer Brothers $1.29/share acquisition) providing liquidity. Forward-looking catalysts include Q3 2026 deal closes (SSR, Farmer) and earnings (Babcock 3/16), while portfolio-level patterns reveal energy/healthcare leading refinancings but tech/microcaps highest distress (delistings, bankruptcies). Overall, implies bottoming distress with recovery potential for refinanced names, but speculative trading risks in bankrupt/delisted firms.

45 high priority45 total filings

🇺🇸United States·March 04, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 04, 2026

Charles & Colvard Ltd's voluntary Chapter 11 bankruptcy filing on March 2, 2026, represents the sole but highly material event in the USA Bankruptcy & Insolvency stream, signaling acute corporate distress with no offsetting positive developments across the filing. While specific period-over-period financial comparisons are not detailed, the petition implies prolonged liquidity pressures culminating in insolvency, with the company operating as a debtor-in-possession (DIP) and seeking first-day relief for critical payments like employee wages, vendors, insurance, and taxes. Potential defaults under the June 24, 2025 Convertible Secured Note with Ethara Capital LLC and lease with SBP Office Owner, L.P., could accelerate obligations, though stayed by bankruptcy law. Equity trading is deemed highly speculative, with shareholders at risk of significant or complete loss depending on restructuring outcomes. This filing underscores portfolio-level risks in distressed names, advising immediate equity avoidance and monitoring for creditor recoveries or asset sales. Negative sentiment dominates at 10/10 materiality, with no bullish insider activity, capital allocation, or guidance changes evident.

1 high priority1 total filings

🇺🇸United States·March 03, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 03, 2026

Across 44 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes include proactive debt refinancing and covenant relief (e.g., 10+ amendments/extensions providing liquidity runway), healthcare/biotech M&A and settlements amid distress signals (12 filings), and equity raises/buybacks signaling confidence in select names despite Nasdaq deficiencies and delistings (4 cases). Period-over-period trends are sparse but reveal mixed revenue performance: Evolus +14% YoY Q4/+12% FY 2025 revenue with GAAP profitability in Q4, contrasting RYAM's -1% YoY Q4 sales and worsening $21M loss; no broad margin compression but operational cash strains in 3 names (e.g., RYAM -$88M Adj FCF). Critical developments: Trinseo NYSE delisting (immediate suspension), Karyopharm going concern doubt tied to $25M equity raise by June 2026, and Arbutus/Genevant $2.25B Moderna settlement (upfront July 2026). Portfolio-level patterns show 15/44 positive sentiments (refinancings, acquisitions), 8 negative (delistings, deficiencies), with healthcare (18/44) dominant for distress signals but also opportunities; implications favor monitoring liquidity extensions as buyout catalysts while avoiding delisting risks.

44 high priority44 total filings

🇺🇸United States·March 02, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 02, 2026

Across 49 filings in the USA Corporate Distress & Bankruptcy stream, a bifurcated landscape emerges: 7 companies (14%) face acute delisting risks or compliance issues (e.g., Allurion, Graphjet, Iterum), while 70% involve proactive capital raises, debt refinancings, or M&A to extend runways amid distress signals, with no broad YoY revenue declines but frequent mentions of prior weak equity/market cap metrics. Biotech/pharma dominates (20+ filings) with mixed M&A outcomes like Pulmatrix termination but Gyre-Cullgen pivot, alongside heavy equity/debt issuances (e.g., $250M Zymeworks royalty note, $1.5B Targa notes) signaling liquidity preservation over growth. Forward-looking catalysts cluster in Q2 2026 (merger closes, approvals), with capital allocation tilting to debt exchanges/raises vs buybacks/dividends, reflecting strained balance sheets. Portfolio-level trends show 12/49 positive financings extending runway >2028 (e.g., Zymeworks beyond 2028), but 5 mixed restructurings introduce dilution risks. Implications: Short small-cap distress names pre-delisting, long M&A targets at premiums (AES 40.3%), monitor Q2 catalysts for turnarounds.

49 high priority49 total filings